Shari Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shari Lau has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Merone Roose-Girma
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
2 shared publications - Annie Ogasawara
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication - Anwesha Dey
Genentech
1 shared publication - Barzin Y. Nabet
Genentech, South San Francisco, USA
1 shared publication - Benjamin Haley
Department of Molecular Biology, Genentech, Inc., San Francisco, USA
1 shared publication - Bridget Hough
Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publication
Latest Publications
- Open Access
- 8 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (19) , eaea6842
Loss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity
Checkpoint inhibitors targeting PD-1 and CTLA-4 have transformed cancer therapy. Both are genetically associated with autoimmune disorders. Moreover, certain immune-related adverse events and autoimmune risk variants are linked to the clinical efficacy of checkpoint inhibition. These associations suggest common principles governing successful cancer immunotherapy and autoimmune susceptibility. Here, we show that ablation of the cytosolic DNA exonuclease TREX1 predisposes mice to autoimmunity while promoting robust antitumor immunity. Constitutive TREX1 loss leads to early onset autoimmunity, characterized by multiorgan CD8+ T cell infiltration, myocarditis, and Sjögren’s syndrome–like disease. In contrast, induced systemic TREX1 ablation is well tolerated and promotes effective CD8+ T cell–driven antitumor immunity. Detailed phenotypic studies revealed a notable overlap between productive antitumor and pathogenic autoimmune CD8+ T cell responses. Collectively, we provide mechanistic evidence for interrelated mechanisms underlying autoimmunity and successful cancer immunotherapy, uncover key parallels between adaptive T cell and innate immune checkpoints, and suggest that targeting autoimmune risk genes represents a promising future avenue for cancer immunotherapy.
- 8 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (19) , eaea6842
Open AccessLoss of the autoimmune risk gene TREX1 reveals a convergence of mechanisms promoting immune tolerance loss and antitumor immunity
Checkpoint inhibitors targeting PD-1 and CTLA-4 have transformed cancer therapy. Both are genetically associated with autoimmune disorders. Moreover, certain immune-related adverse events and autoimmune risk variants are linked to the clinical efficacy of checkpoint inhibition. These associations suggest common principles governing successful cancer immunotherapy and autoimmune susceptibility. Here, we show that ablation of the cytosolic DNA exonuclease TREX1 predisposes mice to autoimmunity while promoting robust antitumor immunity. Constitutive TREX1 loss leads to early onset autoimmunity, characterized by multiorgan CD8+ T cell infiltration, myocarditis, and Sjögren’s syndrome–like disease. In contrast, induced systemic TREX1 ablation is well tolerated and promotes effective CD8+ T cell–driven antitumor immunity. Detailed phenotypic studies revealed a notable overlap between productive antitumor and pathogenic autoimmune CD8+ T cell responses. Collectively, we provide mechanistic evidence for interrelated mechanisms underlying autoimmunity and successful cancer immunotherapy, uncover key parallels between adaptive T cell and innate immune checkpoints, and suggest that targeting autoimmune risk genes represents a promising future avenue for cancer immunotherapy.
- 19 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 364 (6437) , 283-285
Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1
Tissue specificity of tumor suppression: It is well known that the loss of tumor suppressor genes leads to a limited subset of cancers in specific tissues. But why just those tissues? He et al. found a relatively simple explanation for how this tissue selectivity works for the tumor suppressor BAP1 using a mouse model of BAP1-induced cancer. In most cells, loss of BAP1 caused cell death or apoptosis. But in the tissues that formed tumors, differences in the regulation of genes with antiapoptotic effects allowed the cells to survive, even though BAP1 was lost. At least for this one tumor suppressor, its inactivation would normally cause a cell to die; however, this mechanism is absent in a subset of tissues, allowing the cells to proliferate and cause a tumor. Science , this issue p. 283
- 19 April 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 364 (6437) , 283-285
Intrinsic apoptosis shapes the tumor spectrum linked to inactivation of the deubiquitinase BAP1
Tissue specificity of tumor suppression: It is well known that the loss of tumor suppressor genes leads to a limited subset of cancers in specific tissues. But why just those tissues? He et al. found a relatively simple explanation for how this tissue selectivity works for the tumor suppressor BAP1 using a mouse model of BAP1-induced cancer. In most cells, loss of BAP1 caused cell death or apoptosis. But in the tissues that formed tumors, differences in the regulation of genes with antiapoptotic effects allowed the cells to survive, even though BAP1 was lost. At least for this one tumor suppressor, its inactivation would normally cause a cell to die; however, this mechanism is absent in a subset of tissues, allowing the cells to proliferate and cause a tumor. Science , this issue p. 283